Anti-Human CD33, PE conjugated, clone 6C5

CD33 is a 67 kD type I transmembrane glycoprotein also known as Siglec-3, gp67, and p67. It is a sialoadhesion immunoglobulin superfamily member expressed on myeloid progenitors, monocytes, granulocytes, dendritic cells and mast cells. CD33 is absent on normal platelets, lymphocytes, erythrocytes and hematopoietic stem cells. CD33 functions as a sialic acid-dependent cell adhesion molecule with carbohydrate/lectin binding activity. Protein function: Sialic-acid-binding immunoglobulin-like lectin (Siglec) that plays a role in mediating cell-cell interactions and in maintaining immune cells in a resting state (PubMed:10611343, PubMed:15597323, PubMed:11320212). Preferentially recognizes and binds alpha-2,3- and more avidly alpha-2,6-linked sialic acid-bearing glycans (PubMed:7718872). Upon engagement of ligands such as C1q or syalylated glycoproteins, two immunoreceptor tyrosine-based inhibitory motifs (ITIMs) located in CD33 cytoplasmic tail are phosphorylated by Src-like kinases such as LCK (PubMed:28325905, PubMed:10887109). These phosphorylations provide docking sites for the recruitment and activation of protein-tyrosine phosphatases PTPN6/SHP-1 and PTPN11/SHP- 2 (PubMed:10556798, PubMed:10206955, PubMed:10887109). In turn, these phosphatases regulate downstream pathways through dephosphorylation of signaling molecules (PubMed:10206955, PubMed:10887109). One of the repressive effect of CD33 on monocyte activation requires phosphoinositide 3-kinase/PI3K (PubMed:15597323). [The UniProt Consortium]